Bushu Pharma will attend DCAT Week 2023, from 20-23 March, at the InterContinental in New York Barclay.
Bushu Pharma is pleased to announce the completion of the transfer of FUKUSHIMA Factory's business. With the completion of the business transfer, the name of the factory will be changed to Aizu Factory, and it will help further growth as an important production base for Bushu Pharma, which provides high quality pharmaceutical products as a contract manufacturing factory.
Bushu Pharma provides contract manufacturing services for the production of granules, powders, tablets and capsules, Plain tablets, Film-coated tablets, Sugar-coated tablets, Multi-layer tablets, Orally disintegrating tablets, Hard capsules, oral jelly and more
Our recently launched Gateway to Asia service allows you to import bulk products into Japan for quality inspection, labeling, packaging and distribution across Japan and to other Asian countries. Cut down on lead time and inventory management with our Asia Hub Solution.
Ensuring your product has no defects is essential to your success in any market. Bushu Pharma has built its expertise in Visual Inspection. We have the know-how and equipment to expertly conduct inspection of your product – checking for visual defects of both the product and packaging.
We accommodate the strong expansion of temperature-controlled bio-pharmaceuticals (2 to 8°C) for the global markets. One is Misato Cold Chain Center (498 pallets), the new cold chain center for packaging & storage, and another is Kawagoe Cold storage warehouse (500 pallets).
Japan’s premier CDMO.
Offering the best in Pharmaceutical Manufacturing & Supply Chain solutions.
Proven Track-record + Global Capabilities
Years as CDMO
GMP Global Certifications
Percentage of Commercial Product Accounts from Foreign-affiliated Clients
Bushu Pharma will attend DCAT Week 2023, from 20-23 March, at the InterContinental in New York Barclay. We’re looking forward to reconnecting with old colleagues and meeting new ones.
KKR, a leading global investment firm, and Bushu Pharmaceuticals Ltd. (“Bushu Pharma” or the “Company”) today announced the signing of definitive agreements under which KKR will acquire all shares in Bushu Pharma from BPEA EQT. Following the transaction’s completion, KKR aims to accelerate Bushu Pharma’s growth and further position the Company as a leading contract development and manufacturing organization (“CDMO”) for the pharmaceuticals market in Japan and worldwide.
Bushu Pharmaceutical is shortlisted in the “Supply Chain, Logistics & Distribution” category of the CPHI Pharma Awards
We are humbled with the great news received from CPHI today.
Bushu Pharmaceutical is shortlisted in the “Supply Chain, Logistics & Distribution” category of the CPHI Pharma award for our unique supply chain management service, Gateway to Asia.
Visit us at Messe Frankfurt Hall 9 Booth 90F83 to discuss the business possibilities including Gateway to Asia.
Bushu Pharmaceuticals will participate in CPHI Worldwide 2022 in Frankfurt for the first time in three years.
Bushu Pharma is thrilled to be participating at this year’s CPHI Worldwide 2022 in Frankfurt for the first time in three years.
Talk to us about our Gateway to Asia supply chain services that will allow you to expand into Japan and Asia.
With Japan and Asia such an attractive market, this will be an ideal opportunity for your business expansion.
We look forward to seeing you!